Acadian Asset Management LLC purchased a new stake in shares of Moderna, Inc. ( NASDAQ:MRNA – Free Report ) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 7,585 shares of the company’s stock, valued at approximately $900,000.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Ogorek Anthony Joseph NY ADV purchased a new position in shares of Moderna in the 4th quarter worth approximately $27,000. Cedar Wealth Management LLC boosted its holdings in shares of Moderna by 45.
0% in the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after purchasing an additional 90 shares during the period. Westside Investment Management Inc.
purchased a new position in shares of Moderna in the 1st quarter worth approximately $32,000. Family Firm Inc. purchased a new position in shares of Moderna in the 2nd quarter worth approximately $33,000.
Finally, Rise Advisors LLC boosted its holdings in shares of Moderna by 953.3% in the 1st quarter. Rise Advisors LLC now owns 316 shares of the company’s stock worth $34,000 after purchasing an additional 286 shares during the period.
75.33% of the stock is owned by institutional investors. Analyst Upgrades and Downgrades A number of brokerages have recently commented on MRNA.
Oppenheimer cut Moderna from an “outperform” rating to a “market perform” rating in a report on Friday. The Goldman Sachs Group dropped their target price on Moderna from $178.00 to $139.
00 and set a “buy” rating for the company in a report on Monday. Barclays dropped their target price on Moderna from $155.00 to $125.
00 and set an “overweight” rating for the company in a report on Monday. Piper Sandler dropped their price objective on Moderna from $157.00 to $115.
00 and set an “overweight” rating for the company in a report on Friday. Finally, Needham & Company LLC restated a “hold” rating on shares of Moderna in a report on Friday. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and four have given a buy rating to the stock.
According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $103.93.
Moderna Trading Up 1.3 % Shares of NASDAQ MRNA opened at $69.17 on Tuesday.
The company has a quick ratio of 3.92, a current ratio of 4.09 and a debt-to-equity ratio of 0.
05. The business has a fifty day simple moving average of $94.12 and a two-hundred day simple moving average of $111.
72. The firm has a market cap of $26.51 billion, a PE ratio of -4.
41 and a beta of 1.67. Moderna, Inc.
has a twelve month low of $62.55 and a twelve month high of $170.47.
Moderna ( NASDAQ:MRNA – Get Free Report ) last issued its earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.
47) by $0.14. The business had revenue of $241.
00 million during the quarter, compared to analyst estimates of $128.41 million. Moderna had a negative return on equity of 21.
35% and a negative net margin of 116.18%. Moderna’s revenue was down 29.
9% on a year-over-year basis. During the same period in the previous year, the company posted ($3.62) EPS.
Analysts expect that Moderna, Inc. will post -9.52 earnings per share for the current fiscal year.
Insider Buying and Selling at Moderna In other news, Director Noubar Afeyan sold 15,000 shares of the business’s stock in a transaction on Wednesday, June 26th. The stock was sold at an average price of $127.22, for a total value of $1,908,300.
00. Following the completion of the transaction, the director now directly owns 2,284,015 shares of the company’s stock, valued at approximately $290,572,388.30.
The transaction was disclosed in a filing with the SEC, which is available at this hyperlink . In other news, Director Noubar Afeyan sold 15,000 shares of the business’s stock in a transaction on Wednesday, June 26th. The stock was sold at an average price of $127.
22, for a total value of $1,908,300.00. Following the completion of the transaction, the director now directly owns 2,284,015 shares of the company’s stock, valued at approximately $290,572,388.
30. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink . Also, CFO James M.
Mock sold 1,321 shares of the business’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.
19. Following the completion of the transaction, the chief financial officer now directly owns 8,600 shares of the company’s stock, valued at $682,754. The disclosure for this sale can be found here .
Insiders sold a total of 93,158 shares of company stock valued at $11,167,312 in the last ninety days. Corporate insiders own 15.70% of the company’s stock.
Moderna Profile ( Free Report ) Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. Featured Articles Five stocks we like better than Moderna How to Calculate Retirement Income: MarketBeat’s Calculator Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible 3 Stocks to Consider Buying in October Roblox’s Growth Beyond Kids: Stock Set for Major Moves Do Real Estate Investment Trusts Deserve a Place in Your Portfolio? 5 Oversold Stocks to Buy Right Now Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.
com's FREE daily email newsletter ..
Business
Acadian Asset Management LLC Purchases New Position in Moderna, Inc. (NASDAQ:MRNA)
Acadian Asset Management LLC purchased a new stake in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 7,585 shares of the company’s stock, valued at approximately $900,000. A number of other hedge funds [...]